Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Primary Myelofibrosis 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia 1

Interventions

pembrolizumab 242Carboplatin 135Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Bevacizumab 95Cyclophosphamide 93Dexamethasone 78Injections 75Docetaxel 72Pemetrexed 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 60130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 56Ipilimumab 54fludarabine 47Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × KB004 × Clear all
NCT01211691 2015-11-17

Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

Humanigen, Inc.

Phase 1/2 Suspended
120 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡